Enroll faster.
Spend smarter.
Know everything.
Trial Foundry replaces legacy CTMS with AI that actually thinks. Swarm simulations predict enrollment outcomes before you recruit a single patient. Autonomous agents run your sites. Real-time intelligence keeps you ahead of competitors, regulators, and safety signals.
Everything your trial needs. Nothing it doesn't.
Six integrated modules that replace your CTMS, signal monitoring, recruitment platform, and half your spreadsheets.
Swarm Simulations
Monte Carlo simulations powered by LLM reasoning agents. Model enrollment scenarios, budget allocation, and competitive dynamics before recruiting a single patient. Each agent has its own mental model of site behavior.
TrialClaw Site Agents
Six specialized AI agents deployed at every site — Intake, Recruiter, Scheduler, Watchdog, Quartermaster, Dispatch. They handle screening, scheduling, risk flagging, supply management, and inter-site coordination autonomously.
Real-Time Intelligence
Continuous signal ingestion from FDA, PubMed, ClinicalTrials.gov, FAERS, eCFR, and X.com. AI classifies, scores, and routes every signal. Breaking alerts surface safety signals days before formal FAERS reports.
Digital Twins
Non-PII synthetic patient cohorts built from trial demographics and regional health data. Test protocol changes, predict enrollment bottlenecks, and optimize site selection without touching real patient data.
Enrollment Engine
AI-optimized patient recruitment across digital channels. Automated audience targeting, creative generation with IRB compliance review, budget pacing, and real-time A/B testing — all managed by AI.
GUARDIAN Agent
Regulatory compliance agent monitoring ICH-GCP, FDA, EMA, PMDA, ANVISA, TGA, NMPA, and CDSCO requirements. Automated protocol deviation detection, SAE/SUSAR tracking, and multi-jurisdiction audit trail.
Industry Pulse
Real-time signal feed from 7 sources. AI classifies, scores relevance, and routes to your team — automatically.
FDA Issues Updated Guidance on Decentralized Trial Endpoints
New draft guidance expands acceptable digital endpoints for DCTs, including patient-reported outcomes via mobile apps.
@DrSarahChenMD: DCT Endpoint Validation Data Released
94% concordance between digital and in-clinic HbA1c measurements across 1,200 patients. Major validation for decentralized endpoints.
Elevated GI Events in Semaglutide Combination Therapy
2.3x expected reporting rate for GI adverse events in semaglutide + metformin over the past 90 days.
Meta-Analysis: Digital Recruitment Outperforms Traditional by 2.4x
Systematic review of 47 RCTs shows digital-first recruitment achieves 2.4x enrollment velocity at 40% lower cost.
Pfizer Q1 Earnings: GLP-1 Pipeline Expansion Confirmed
Three new Phase II trials expected to open enrollment by Q3 2026. Increasing competitive pressure in T2D space.
Competing GLP-1 Trial Opens 12 New Sites in Southeast
VERTEX-GLP1 activated 12 sites across FL, GA, TX — 4 overlap with BEACON-DM catchment areas.
Built for the edge. Designed for scale.
Cloudflare Workers, Neon Postgres, Convex real-time, and dedicated GPU inference. Zero cold starts. Global edge deployment.
Your trials deserve better than spreadsheets.
See how Trial Foundry accelerates enrollment, cuts costs, and surfaces intelligence your competitors miss.